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Objective: To assess the efﬁcacy and safety of everolimus in Japanese patients with meta-
static renal cell carcinoma.
Methods: A subgroup analysis of the pivotal Phase III, randomized, double-blind, placebo-
controlled trial of everolimus 10 mg/day in patients with disease progression after treatment
with sorafenib, sunitinib or both assessed outcomes in Japanese participants. Results were
compared with those for the overall study population.
Results: The ﬁnal trial analysis included 24 Japanese patients (everolimus, n ¼ 15; placebo,
n ¼ 9). Median progression-free survival in the Japanese subpopulation was 5.75 months (95%
conﬁdence interval, 4.90 months to not reached) with everolimus and 3.61 months (95% conﬁ-
dence interval, 1.91–9.03 months) with placebo (hazard ratio, 0.19; 95% conﬁdence interval,
0.05–0.83). Median overall survival was not reached with everolimus and was 14.9 months
(95% conﬁdence interval, 11.0–16.8 months) with placebo (hazard ratio, 0.30; 95% conﬁdence
interval, 0.07–1.27). Overall, efﬁcacy and safety were similar when comparing the Japanese
and overall populations. In the Japanese subpopulation, the most common adverse events with
everolimus were stomatitis, infections and rash. Four Japanese subjects (27%) developed
Grade 1 (n ¼ 2) or 2 (n ¼ 2) pneumonitis (all reversible and allowing for continuation of therapy,
after interruption, steroids and dose reduction for both Grade 2 cases), with a lower pneumonitis
incidence of 14% in the overall population (albeit associated with a Grade 3 incidence of 4%).
Conclusions: These ﬁndings suggest that the demonstrated beneﬁts of everolimus in the
overall trial population are similar in Japanese patients with metastatic renal cell carcinoma.
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INTRODUCTION
The incidence of renal cell carcinoma (RCC) in Japan is
increasing. Results of a survey conducted from January 2002
through December 2002 in all 47 prefectures revealed the
crude incidence rates of RCC to be 8.2 males and 3.6
females per 100 000 persons, an increase of 1000
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ducted 1997 survey (1). In general, approximately one-third of
patients with RCC present with metastatic disease (mRCC),
which has a 5 year survival rate of 10% (2).
The vascular endothelial growth factor receptor-tyrosine
kinase inhibitors (VEGFr-TKI) sorafenib and sunitinib are
now approved in Japan, Europe and the USA for the treat-
ment of unresectable or metastatic RCC based on their
demonstrated beneﬁt in clinical trials (3,4). These targeted
agents have become the standard therapy for mRCC. Until
recently, however, no standard therapy existed for patients
with mRCC that progressed after treatment with VEGFr-
TKI-targeted agents.
Everolimus is an orally administered inhibitor of the mam-
malian target of rapamycin (mTOR) and was approved by
the United States Food & Drug Administration (US FDA) in
March 2009, the European Medicines Agency (EMEA) in
August 2009 and in Japan in January 2010 for the treatment
of unresectable or metastatic RCC. mTOR is a cytoplasmic
serine/threonine kinase that acts as an integration point for
three key inputs: (i) extracellular stimulation by growth
factors including VEGF; (ii) nutrient availability; and (iii)
intracellular energy status. The convergence of these
upstream signals, combined with positive and negative feed-
back mechanisms, determines whether mTOR is activated.
Once activated, mTOR initiates a downstream cascade that
triggers the cell’s translational machinery to produce proteins
required for a variety of cellular functions, including metab-
olism, growth, proliferation and angiogenesis. Dysregulation
of signaling elements both upstream and downstream of
mTOR has been implicated in many cancers (5–8).
In a Phase II trial, everolimus demonstrated antitumor
activity in patients with mRCC who experienced disease pro-
gression after treatment with cytokines, chemotherapy or
erlotinib and bevacizumab (9). Everolimus was subsequently
evaluated in RECORD-1 (Renal Cell cancer treatment with
Oral RAD001 given Daily), the pivotal, Phase III, random-
ized, placebo-controlled trial of patients with mRCC who
had progressed on VEGFr-TKI. Results of this trial,
which enrolled patients from 10 countries, including Japan,
led to the US FDA and EMEA approval of everolimus.
RECORD-1 demonstrated that treatment with everolimus
plus best supportive care (BSC) prolonged progression-free
survival (PFS) compared with placebo plus BSC (4.9 vs. 1.9
months, respectively; P , 0.001; hazard ratio [HR],
0.33; 95% conﬁdence interval [CI], 0.25–0.43) (10).
Consequently, everolimus represents a viable treatment
option for patients with VEGFr-TKI-refractory disease.
Results of a Phase I clinical and pharmacokinetic study of
everolimus in previously treated Japanese patients with
advanced solid tumors demonstrated that its pharmacoki-
netics and tolerability were similar to those observed in pre-
vious studies with large populations of Caucasian patients,
for whom the most common drug-related toxicities included
rash, stomatitis and fatigue. No dose-limiting toxicities were
noted (11). The current analysis was initiated to assess the
efﬁcacy and safety of everolimus in the Japanese subgroup
of patients who participated in RECORD-1.
PATIENTS AND METHODS
PATIENTS
The RECORD-1 inclusion and exclusion criteria have been
described in detail previously (12). Brieﬂy, patients 18 years
of age were eligible for enrollment if they had been diagnosed
with metastatic carcinoma and had histologic or cytologic con-
ﬁrmation of clear cell RCC, had measurable disease, showed
disease progression on or within 6 months of treatment with
sunitinib, sorafenib or both, and exhibited adequate Karnofsky
performance status (70%), blood counts and serum chem-
istry. Prior therapy with bevacizumab and cytokines was per-
mitted. Written informed consent was obtained from each
patient before screening procedures were initiated.
STUDY DESIGN
RECORD-1 was a prospective, randomized, double-blind,
placebo-controlled, international, multicenter, parallel-group
Phase III trial (NCT00410124). It contained ﬁve phases: (i)
screening/baseline; (ii) blinded treatment; (iii) open-label
treatment; (iv) follow-up; and (v) extension treatment. The
study design incorporated two planned interim analyses and
a ﬁnal analysis. The protocol speciﬁed that the interim ana-
lyses were to be carried out when 30 and 60% of the 290
PFS events (per central radiology) required for the ﬁnal
analysis had been reached. The protocol and all amendments
issued prior to or during the study were reviewed by the
local independent ethics committee or institutional review
board for each center, and the study was conducted accord-
ing to the ethical principles of the Declaration of Helsinki.
Patients were randomized in a 2:1 ratio to receive everoli-
mus 10 mg/day (n ¼ 277) or matching placebo (n ¼ 139) in
conjunction with BSC. Randomization was stratiﬁed by the
number of prior VEGFr-TKI therapies (1 or 2) and
Memorial Sloan-Kettering Cancer Center (MSKCC) prog-
nostic criteria for patients with previously treated mRCC
(favorable, intermediate or poor) (10,13). Treatment cycles
were 28 days in length.
Patients continued on blinded treatment until tumor pro-
gression or unacceptable toxicity, death or discontinuation
for any other reason. Dose modiﬁcations were permitted for
clinically signiﬁcant hematologic or other adverse events, as
described previously (12). Patients randomized to receive
placebo who demonstrated evidence of progression by inves-
tigator assessment were unblinded and permitted to cross
over to receive open-label everolimus (12).
EFFICACY ANALYSES
The primary efﬁcacy endpoint was PFS by central review.
Tumor response was assessed at scheduled intervals with the
18 Everolimus in Japanese patients with mRCCResponse Evaluation Criteria in Solid Tumors (RECIST)
(14), based on imaging studies by the investigators and
independent central radiology review (12). Secondary efﬁ-
cacy endpoints included overall survival (OS) and tumor
response.
SAFETY ANALYSES
Safety analyses were carried out as described previously
(12). Brieﬂy, all adverse events were monitored and
recorded, and laboratory parameters, vital signs, physical
examinations and concomitant therapies were assessed regu-
larly and recorded. The National Cancer Institute’s Common
Terminology Criteria (NCI-CTC) version 3.0 were used to
grade adverse events and laboratory abnormalities (12). To
detect radiologic lung changes suggestive of pneumonitis, a
central radiology review of chest computed tomography
scans and chest X-rays was performed.
STATISTICAL ANALYSES
The full analysis set included all randomized patients; the
safety population consisted of all patients who received at
least one dose of study drug and who had at least one post-
baseline safety assessment.
P F Sa n dO Sc u r v e si ne a c ht r e a t m e n tg r o u pw e r ee s t i -
mated with Kaplan–Meier analysis. HR for the Japanese
subpopulation was obtained from an unstratiﬁed Cox pro-
portional hazard model. As previously reported for the
overall population (12), PFS and OS were statistically com-
pared among the groups with a stratiﬁed, one-sided log-rank
test, adjusting for strata deﬁned by the MSKCC risk criteria.
HRs were obtained from a stratiﬁed Cox proportional
hazards model, using the strata deﬁned by the MSKCC risk
criteria.
The blinded phase of RECORD-1 was stopped on 28
February 2008, based on the efﬁcacy of everolimus shown in
the second interim analysis (10). Compared with data for the
second interim analysis (collected up to 15 October 2007;
191 PFS events), data for the ﬁnal analysis were based on 75
additional PFS events, 6 additional patients accrued and 4.5
months of additional blinded follow-up. The cutoff date of
follow-up for OS was 15 November 2008.
RESULTS
PATIENT DEMOGRAPHICS AND DISPOSITION
Of the 416 patients randomized to treatment in the overall
trial, the subpopulation of Japanese patients in the ﬁnal analy-
sis included 15 patients who received everolimus and 9
patients who received placebo. The baseline characteristics
and prior therapies of these 24 Japanese patients and the 416-
patient overall population are shown in Table 1 (10). The
Japanese subpopulation was 79% male and the median age
was 63.5 years. The Japanese subpopulation was similar to
the overall trial population, with the exceptions that the pre-
dominant VEGFr-TKI therapy of the Japanese patients was
sorafenib instead of sunitinib and that almost all Japanese
patients had received prior treatment with interferon.
By the end of the double-blind phase, ﬁve Japanese
patients in the everolimus group had discontinued (disease
progression, n ¼ 4; withdrew consent, n ¼ 1) and eight
patients in the placebo group had discontinued (all due to
disease progression). These eight patients from the placebo
group then crossed over to receive open-label everolimus.
All 24 Japanese patients were included in the full analysis
set and in the safety population. In the overall population,
202 patients in the everolimus group and 133 patients in the
placebo group had discontinued therapy, with the primary
reasons being disease progression and adverse events in the
Table 1. Baseline characteristics and prior therapies in RECORD-1 (10)










Female 61 (22) 33 (24) 1 (7) 4 (44)
Male 216 (78) 106 (76) 14 (93) 5 (56)
Median age
(range), year
61 (27–85) 60 (29–79) 65 (48–77) 62 (46–73)





29/56/14 28/57/15 33/60/7 44/44/11
Sites of metastases, %
Lung 73 81 87 89
Bone 37 30 33 11
Liver 33 38 20 33
Prior therapies, %
Nephrectomy 97 96 100 100
Radiotherapy 31 27 20 11
VEGFr-TKI therapy
Sunitinib 45 43 13 22
Sorafenib 29 31 80 78
Both 26 26 7 0
Other systemic therapy
Immunotherapy 65 67 100 89




Other 5 3 0 0
KPS, Karnofsky performance status; MSKCC, Memorial Sloan-Kettering
Cancer Center; VEGFr-TKI, vascular endothelial growth factor
receptor-tyrosine kinase inhibitor.
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disease progression and death for the placebo group (n ¼
124 and n ¼ 4, respectively).
TREATMENT ADMINISTRATION
The median duration of treatment in the Japanese subpopu-
lation was 135 days in the everolimus group and 96 days in
the placebo group (overall population: 141 and 60 days,
respectively). The median cumulative dose of everolimus
was 1160 mg, the median dose intensity was 9.9 mg/day and
the median relative dose intensity was 0.99 (overall popu-
lation: 1252.5 mg, 10.0 mg/day and 1.0, respectively). In the
Japanese subpopulation, dose reduction and/or interruption
was necessary in eight patients in the everolimus group
(53.3%; for ﬁve of eight patients, this was due to an adverse
event) and in no patients in the placebo group; corresponding
rates for the overall population were 46 and 15%, respect-
ively, most commonly for an adverse event in both groups
(39 and 9%, respectively).
EFFICACY ASSESSMENT
Everolimus appeared to prolong PFS compared with placebo
in the Japanese subpopulation. By independent central radi-
ology review, median PFS was 5.75 months (95% CI, 4.90
months to not reached) with everolimus and 3.61 months
(95% CI, 1.91–9.03 months) with placebo (Fig. 1A). The HR
was 0.19, with a 95% CI of 0.05–0.83. In the overall popu-
lation, median PFS was 4.90 months (95% CI, 3.98–5.52
months) with everolimus and 1.87 months (95% CI, 1.84–
1.94 months) with placebo, translating into a highly signiﬁ-
cant HR of 0.33 (95% CI, 0.25–0.43; P , 0.001; Fig. 1B).
Median OS in the Japanese subpopulation was not reached
in the everolimus group and was 14.9 months (95% CI,
11.0–16.8 months) in the placebo group at the cutoff date of
15 November 2008 (Fig. 2A). The HR was 0.30, with a 95%
CI of 0.07–1.27. There were no on-treatment deaths among
Japanese patients in either treatment group. One Japanese
patient who had been treated with everolimus died during
the follow-up period, over 6 months after the last dose. In
the overall population, median OS was 14.8 months with
everolimus and 14.4 months with placebo, translating into a
non-signiﬁcant HR of 0.87 (95% CI, 0.65–1.17; P ¼ 0.16;
Fig. 2B) that was inﬂuenced by the 80% rate of crossover
from placebo to open-label everolimus (10).
The best overall response based on central radiologic
assessment was stable disease (SD) in 14 of 15 patients who
received everolimus (the response of 1 patient was unknown)
and SD in 6 of 9 patients who received placebo (the other 3
patients had progressive disease). No patient achieved a
partial response (PR) at the ﬁnal analysis, but in a sub-
sequent efﬁcacy assessment made in an open-label extension
phase only for Japanese subjects, one patient achieved a PR
as an investigator-assessed best overall response. In the
overall population, the SD rates were 185 of 277 (67%) with
everolimus and 45 of 139 (32%) with placebo, with an
additional 5 patients in the everolimus group (1.8%) achiev-
ing a PR.
SAFETY
As summarized in Table 2, stomatitis, infections and rash
were the predominant adverse events among Japanese
patients in the everolimus group during the blinded-study
phase, with incidences that were notably higher than the
incidences in the overall population. Most adverse events
were mild (Grade 1) to moderate (Grade 2) in severity and
were resolved with dose interruption and/or reduction. In the
Japanese subpopulation, there were two reports of Grade 2
interstitial lung disease and two reports of Grade 1 pneumo-
nitis during everolimus therapy, for a total on-treatment
occurrence of pneumonitis (based on grouped terms) of
27%. The corresponding pneumonitis incidence among the
everolimus group in the overall population was 14%, includ-
i n gG r a d e1 / 2( n ¼ 2 7 )a sw e l la sG r a d e3( n ¼ 10) events.
None of the Japanese patients stopped therapy permanently
because of pneumonitis. With respect to the two Japanese
cases of Grade 2 pneumonitis (reported as interstitial lung
disease), study treatment was interrupted, corticosteroid
therapy was instituted and everolimus was resumed at a
reduced dose, with eventual resolution of the interstitial lung
disease. Despite increased reporting of non-infectious pneu-
monitis for Japanese patients compared with the overall
study population, central review of chest computed tomogra-
phy scans for radiologic lung changes suggestive of pneumo-
nitis found a similar incidence of radiologic changes in the
Japanese and the overall population.
Treatment-related Grade 3/4 adverse events were infre-
quently reported, with no speciﬁc type reported in .1
patient in the Japanese subpopulation (all of which were
Grade 3) and incidences of individual events typically ,5%
in the overall population (with a few exceptions with respect
to laboratory abnormalities). No Grade 4 adverse events
were reported. In the Japanese subpopulation, no adverse
event led to study discontinuation in the double-blind phase,
whereas the adverse event-related discontinuation rates in the
overall population were 13.9 and 2.9% for the everolimus
and placebo groups, respectively. The most common adverse
events resulting in everolimus discontinuation were dyspnea
and pneumonitis (n ¼ 7 [3.6%] for each).
DISCUSSION
The results of RECORD-1 established that daily treatment
with oral everolimus prolongs PFS in patients with mRCC
that has progressed on VEGFr-TKI therapies and generally
is well tolerated, fulﬁlling an unmet medical need in this
patient population. The results of this subgroup analysis of
patients in RECORD-1 suggest that a similar beneﬁt is
expected for Japanese patients.
The Japanese subpopulation analysis was limited by the
small number of patients in the trial (n ¼ 24); however, the
PFS results in the Japanese subgroup aligned with the PFS
20 Everolimus in Japanese patients with mRCCresults obtained in the overall trial population. It was specu-
lated that the longer PFS of both everolimus and placebo
groups in the Japanese subpopulation compared with the
overall population may have been caused by the better overall
condition of patients enrolled in the study. Although OS was
likely confounded by the crossover design of the trial, results
trended toward a beneﬁt for everolimus compared with
placebo, similar to ﬁndings in the overall trial population.
In addition, the types of adverse events occurring in the
Japanese patients were similar to those occurring in
Figure 1. Median progression-free survival in the (A) Japanese subpopulation and (B) overall population (10) of RECORD-1 by central radiology review.
Figure 1B reprinted with permission from Wiley & Sons. Copyright 2010. All rights reserved (10).
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everolimus group was rash, followed in decreasing order
by stomatitis, dysgeusia, diarrhea, epistaxis, cough and per-
ipheral edema. These events also occurred with a relatively
high frequency (10% incidence) in the overall population
of RECORD-1. The pharmacokinetic proﬁle of everolimus
in a Phase I study in previously treated Japanese patients
with advanced solid tumors was similar to that observed in
previous studies with large populations of Caucasian
patients (11), suggesting no difference in treatment
exposure between these two ethnic populations. The
increased incidence of adverse events may be due to
differences in ethnicity, stricter investigation of the
Japanese physicians in identifying adverse events, or the
small number of Japanese patients in this study. Most
adverse events were mild/moderate in severity and there
was no evidence of worsening adverse events. The
majority of adverse events requiring treatment resolved
after dose interruption and/or reduction, and patients were
able to continue receiving everolimus.
Figure 2. Median overall survival in the (A) Japanese subpopulation and (B) overall population (10) of RECORD-1. Figure 2B reprinted with permission
from Wiley & Sons. Copyright 2010. All rights reserved (10).
22 Everolimus in Japanese patients with mRCCTable 2. Incidence of adverse events, irrespective of relationship to treatment and laboratory abnormalities in the Japanese subpopulation of RECORD-1
Overall population Japanese patients
Everolimus (n ¼ 274),
n (%)
Placebo (n ¼ 137),
n (%)
Everolimus (n ¼ 15),
n (%)
Placebo (n ¼ 9),
n (%)
All Grades Grade 3/4 All Grades Grade 3/4 All Grades Grade 3/4 All Grades Grade 3/4
Adverse event
a (total) 265 (97) 142 (52)/36 (13) 128 (93) 32 (23)/7 (5) 15 (100) 6 (40)/0 5 (56) 0/0
Stomatitis
b 120 (44) 11 (4)/1 (,1) 11 (8) 0/0 11 (73) 0/0 1 (11) 0/0
Infections
c 101 (37) 19 (7)/7 (3) 25 (18) 2 (1)/0 10 (67) 1 (7)/0 2 (22) 0/0
Rash 80 (29) 3 (1)/0 9 (7) 0/0 10 (67) 0/0 0 0/0
Dysgeusia 28 (10) 0/0 3 (2) 0/0 7 (47) 0/0 0 0/0
Epistaxis 49 (18) 0/0 0 0/0 6 (40) 0/0 0 0/0
Diarrhea 81 (30) 4 (1)/0 9 (7) 0/0 6 (40) 0/0 0 0/0
Cough 82 (30) 2 (,1)/0 22 (16) 0/0 5 (33) 0/0 2 (22) 0/0
Edema peripheral 68 (25) 2 (,1)/0 11 (8) 1 (,1)/0 5 (33) 0/0 0 0/0
Pneumonitis
d 37 (14) 10 (4)/0 0 0/0 4 (27) 0/0 0 0/0
Nail disorder 14 (5) 0/0 0 0/0 4 (27) 0/0 0 0/0
Constipation 53 (19) 1 (,1)/0 24 (18) 1 (,1)/0 4 (27) 0/0 1 (11) 0/0
Anorexia 69 (25) 4 (1)/0 19 (14) 1 (,1)/0 3 (20) 0/0 0 0/0
Cheilitis 4 (1) 0/0 0 0/0 3 (20) 0/0 0 0/0
Eyelid edema 11 (4) 0/0 0 0/0 3 (20) 0/0 0 0/0
Arthralgia 28 (10) 3 (1)/0 14 (10) 2 (1)/0 3 (20) 0/0 1 (11) 0/0
Hemorrhoid 15 (6) 0/0 1 (,1) 0/0 3 (20) 0/0 0 0/0
Nausea 72 (26) 4 (1)/0 26 (19) 0/0 3 (20) 0/0 0 0/0
Vomiting 56 (20) 6 (2)/0 16 (12) 0/0 3 (20) 0/0 1 (11) 0/0
Fatigue 84 (31) 15 (6)/0 37 (27) 4 (3)/1 (,1) 3 (20) 0/0 1 (11) 0/0
Pyrexia 54 (20) 2 (,1)/0 12 (9) 0/0 3 (20) 0/0 0 0/0
Laboratory abnormality
Hematology
Hemoglobin decreased 253 (92) 33 (12)/3 (1) 108 (79) 7 (5)/1 (,1) 14 (93) 0/0 6 (67) 0/0
Lymphocytes decreased 139 (51) 43 (16)/6 (2) 39 (28) 7 (5)/0 6 (40) 2 (13)/0 3 (33) 0/0
Platelets decreased 64 (23) 3 (1)/0 3 (2) 0/1 (,1) 4 (27) 1 (7)/0 0 0/0
Neutrophils decreased 37 (14) 0/1 (,1) 5 (4) 0/0 4 (27) 0/0 1 (11) 0/0
Biochemistry
Cholesterol increased 212 (77) 12 (4)/0 48 (35) 0/0 13 (87) 0/0 7 (78) 0/0
Triglycerides increased 200 (73) 2 (,1)/0 46 (34) 0/0 9 (60) 1 (7)/0 4 (44) 0/0
Glucose increased 157 (57) 42 (15)/1 (,1) 34 (25) 2 (1)/0 8 (53) 1 (7)/0 0 0/0
Creatinine increased 137 (50) 4 (1)/0 46 (34) 0/0 6 (40) 0/0 3 (33) 0/0
Phosphate decreased 102 (37) 17 (6)/0 11 (8) 0/0 6 (40) 0/0 2 (22) 0/0
Aspartate transaminase increased 68 (25) 1 (,1)/1 (,1) 9 (7) 0/0 4 (27) 0/0 0 0/0
Alanine transaminase increased 58 (21) 3 (1)/0 5 (4) 0/0 5 (33) 0/0 0 0/0
Bilirubin increased 8 (3) 2 (,1)/1 (,1) 3 (2) 0/0 0 0/0 0 0/0
aIncludes events that occurred in 3 patients in the Japanese subpopulation and corresponding data for the overall population. Data for the overall population
are not all inclusive, only capturing the most common events in the Japanese subpopulation.
bIncludes aphthous stomatitis, mouth ulceration and tongue ulceration.
cIncludes all infections.
dIncludes interstitial lung disease, lung inﬁltration, pneumonitis, pulmonary alveolar hemorrhage, alveolitis, pneumopathy and pulmonary toxicity.
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rapamycin and its derivatives, possibly representing a hyper-
sensitivity reaction; however, its etiology has not been fully
characterized (15,16). A diagnosis of non-infectious pneu-
monitis should be considered in patients presenting with
non-speciﬁc respiratory signs and symptoms (to include
pyrexia, cough or dyspnea) and in whom infectious, neoplas-
tic and other non-medicinal causes have been excluded by
appropriate investigation. According to the data reported
here for everolimus in mRCC, the incidence of non-
infectious pneumonitis was increased among Japanese
patients, at 27 vs. 11% for the overall population; the impact
of the small sample size on this disparate ﬁnding is
unknown. However, it was noted during the central review
of results that the radiological changes observed did not
support the higher incidence of non-infectious pneumonitis
reported in Japanese when compared with the overall popu-
lation. Nonetheless, it is encouraging that the four Japanese
cases were limited to Grade 1/2 severity and all were suc-
cessfully managed, resulting in the resolution of the toxicity
and the ability to continue treatment (with treatment
interruption and dose reduction for the 2 patients with
Grade 2 events).
In conclusion, the results of this subgroup analysis suggest
that the beneﬁts of everolimus in Japanese patients with
mRCC are similar to those observed in the overall pivotal
Phase III trial population. These ﬁndings, along with those
of previous studies of everolimus in Japanese patients,
suggest that everolimus is a valuable treatment option for
Japanese patients with mRCC that has progressed on
VEGFr-TKI therapy.
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